- Home
- ESPR vs TRVI Comparison
ESPR vs TRVI Comparison
Compare ESPR & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- TRVI
- Stock Information
- Founded
- ESPR 2008
- TRVI 2011
- Country
- ESPR United States
- TRVI United States
- Employees
- ESPR N/A
- TRVI N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- ESPR Health Care
- TRVI Health Care
- Exchange
- ESPR Nasdaq
- TRVI Nasdaq
- Market Cap
- ESPR 410.2M
- TRVI 341.4M
- IPO Year
- ESPR 2013
- TRVI 2019
- Fundamental
- Price
- ESPR $1.89
- TRVI $4.19
- Analyst Decision
- ESPR Buy
- TRVI Strong Buy
- Analyst Count
- ESPR 6
- TRVI 8
- Target Price
- ESPR $7.25
- TRVI $9.31
- AVG Volume (30 Days)
- ESPR 5.1M
- TRVI 454.6K
- Earning Date
- ESPR 02-25-2025
- TRVI 03-19-2025
- Dividend Yield
- ESPR N/A
- TRVI N/A
- EPS Growth
- ESPR N/A
- TRVI N/A
- EPS
- ESPR N/A
- TRVI N/A
- Revenue
- ESPR $295,451,000.00
- TRVI N/A
- Revenue This Year
- ESPR $186.04
- TRVI N/A
- Revenue Next Year
- ESPR $11.25
- TRVI N/A
- P/E Ratio
- ESPR N/A
- TRVI N/A
- Revenue Growth
- ESPR 187.12
- TRVI N/A
- 52 Week Low
- ESPR $1.58
- TRVI $1.39
- 52 Week High
- ESPR $3.94
- TRVI $4.68
- Technical
- Relative Strength Index (RSI)
- ESPR 39.38
- TRVI 58.00
- Support Level
- ESPR $1.71
- TRVI $3.81
- Resistance Level
- ESPR $2.26
- TRVI $4.30
- Average True Range (ATR)
- ESPR 0.14
- TRVI 0.24
- MACD
- ESPR -0.01
- TRVI 0.01
- Stochastic Oscillator
- ESPR 33.33
- TRVI 86.63
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.